PCSK9 inhibitor – Talk Bio

Actionable Insights Powered by AI

Merck’s Oral PCSK9 Inhibitor Enlicitide Significantly Reduces LDL Cholesterol in Phase 3 Trials

2 months ago talkbio0Tagged Administration of prophylactic statin, cholesterol, CORALreef, CORALreef AddOn, enlicitide, HeFH, Hypercholesterolemia, Familial, Hyperlipidemia, LDL-C, Merck, Oral Therapy, PCSK9 inhibitor

Merck; PCSK9 inhibitor; enlicitide; phase 3 trials; cholesterol; LDL-C; oral therapy; hyperlipidemia; familial hypercholesterolemia; CORALreef HeFH; CORALreef AddOn; statin therapy

AstraZeneca’s oral PCSK9 inhibitor halves cholesterol in phase 2 trial

4 months ago talkbio0Tagged AstraZeneca 's, AZD0780, Effectiveness, LDL Cholesterol Lipoproteins, Oral cavity, PCSK9 inhibitor

AZD0780, LDL Cholesterol Lipoproteins, AstraZeneca ‘s, Oral cavity, PCSK9 inhibitor, Effectiveness